Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...
Nemaura Medical (NASDAQ:NMRD) is a medical tech...
We are a pharmaceutical company currently in the preclinical stage, dedicated to d...
We are a pharmaceutical company currently in th...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
A global leader in DNA sequencing and array-based technologies, Illumina is fuelin...
A global leader in DNA sequencing and array-bas...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
United Therapeutics Corporation focuses on the strength of a balanced, value-creat...
United Therapeutics Corporation focuses on the ...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Join the National Investor Network and get the latest information with your interests in mind.